Viking Therapeutics is gaining attention in the weight loss drug market with positive obesity drug results that are being compared favorably to Novo Nordisk and Lilly. Speculation arises about Viking being a potential takeover target, with analysts predicting a significant increase in share price. Competitors in the GLP-1 obesity space are exploring precision medicine approaches to differentiate themselves from leaders like Wegovy and Zepbound.
StockWatch: Challengers Take Aim at Lilly, Novo Nordisk Viking Therapeutics shares rocket 146% on positive obesity data; Zealand Pharma climbs as 83% of patients show MASH improvement. Learn more: https://t.co/eLnmz5cRFt https://t.co/IRrcjjTdCw
4March: What data generated by @Viking_VKTX's VK2735 and @ZealandPharma's survodutide has impressed investors? And how much are analysts predicting in peak sakes for both drugs? My latest StockWatch for @GENbio: https://t.co/mEnKifhHkU
How potential competitors in the #GLP-1 #obesity space could take a precision medicine approach via @closed_loop_med's technology to differentiate from leaders #Wegovy and #Zepbound $XBI $NVO $LLY https://t.co/HWrNtXEk9S
$VKTX What a move, weight loss drugs the rage. Still, at least 2 years away. FYI CNBC pumping it this weekend 8D needs to catch up https://t.co/Ed2rYJdb9g
$VKTX Don’t really see how Viking isn’t bought out, and it might behoove interested parties to make their move before oral formulation data, if good, cause the next leg up in share price. Can $PFE digest a $20 billion deal? Because they could really use 2735… $XBI
Viking Therapeutics emerges as a strong weight loss drug player — or takeover target https://t.co/IEaXPlGEwk
Viking’s obesity drug results “compare favorably with what we have seen from the likes of” Novo and Lilly, said one analyst. https://t.co/HY6J7egM9l